Shugeng Gao, MD, PhD

Department of Thoracic Surgical Oncology, Cancer Institute & Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, National Cancer Center, Beijing, China

.Prof. Gao Shugeng obtained his Doctorate of Medicine degree in oncology from Peking Union Medical College & Chinese Academy of Medical Sciences (PUMC&CAMS) and then completed his postdoctoral training at the same institution. Currently he is a chief physician and doctoral tutor in PUMC&CAMS and also has been granted as a Fellow of the Royal College of Surgeons (FRCS). He has engaged in the surgical treatment, multidisciplinary therapy, and translational medicine of lung cancer for nearly 30 years.

He is the current director of the Department of Thoracic Surgery of the National Cancer Institute (NCI) and the Cancer Institute/Hospital of the Chinese Academy of Medical Sciences (CICAMS). The department serves as a National Key Clinical Specialty and is the most prestigious clinical department in China. Prof. Gao also has been elected as the vice chairman of Chinese Association of Thoracic Surgeons, member of China Anti-Cancer Association, Associate Editor of Journal of Thoracic Disease, and reviewer of many peer-reviewed journals.

He has been the principal investigator (PI) of multiple multi-center trials on lung cancer since the initiation of the "11th 5-Year Program". In particular, the "Research on the Multidisciplinary Treatment of Lung Cancer", supported by the National Science and Technology Support Program and participated by 48 hospitals from 21 provinces in China, ranked No. 1 among all the completed research projects under the Ministry of Health. In the past five years, he has been focused on lifeomic research and the multidisciplinary treatment and precision medicine of lung cancer. He has been the PIs of the "X-Omics Studies on Lung Cancer and Breast Cancer" (supported by 863 Key Program) and "Improvement and Application of Surgical Procedures for Peripheral Stage Ia Non-small-cell Lung Cancer" (supported by Beijing Municipal Science & Technology Program). He is a key researcher in the "Molecular Typing and Individualized Diagnosis and Treatment Techniques of Lung Cancer" (supported by 863 Key Program) and "Cooperative Study on Molecular Markers for the Early Detection of Lung Cancer and Colorectal Cancer" (an international science and technology cooperation project). In 2016, he served as the PI of the "Study on Precise Prevention, Diagnosis, and Treatment Model of Lung Cancer and Its Standardized Clinical application", a national key R&D project.

He participated in the application for College Science and Technology Progress Award in 2017 and for National Science and Technology Progress Award in 2018. He was the winners of 2017 Chinese Medical Science and Technology Award, Huaxia Medical Science and Technology Award, National Health and Family Planning System Advanced Worker, and Advanced Worker in the Counterpart Support for Xinjiang.